Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02945631 · ClinicalTrials.gov registry record · NA
Quarterback 2b - Sequential Therapy With Reduced Dose Chemoradiotherapy for HPV Oropharynx Cancer
A NA study of Locally Advanced HPV Positive Oropharynx Cancer, sponsored by Icahn School of Medicine at Mount Sinai.
- Active
- Registry status
- NA
- Development phase
- 43
- Enrollment target
- 1
- Study location
NCT02945631 is a NA study of Locally Advanced HPV Positive Oropharynx Cancer that is active but no longer recruiting, run by Icahn School of Medicine at Mount Sinai. The registered enrollment target is 43 participants. The trial reports 1 study location across 1 state.
The verdict
NCT02945631, a NA study of Locally Advanced HPV Positive Oropharynx Cancer, is active but no longer recruiting, sponsored by Icahn School of Medicine at Mount Sinai.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 43 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to establish the efficacy and toxicity of low dose chemoradiotherapy after induction chemotherapy in patients with locally advanced HPV+ oropharynx cancer and establish prognostic factors that would apply to help select patients for this treatment in the future.
Conditions Studied
Interventions
- RADIATION PTV56
- RADIATION PTV50.4
Study Locations (1)
New York
- Icahn School of Medicine at Mount Sinai - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2016-04-25 |
| Est. Completion | 2027-12 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02945631
The ClinicalTrials.gov registry entry for NCT02945631 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 43 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Icahn School of Medicine at Mount Sinai, which has 708 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Locally Advanced HPV Positive Oropharynx Cancer appearing as the primary indexed condition, and to 2 interventions - of which PTV56 is the first listed.
NCT02945631 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT02945631 about?
NCT02945631 is a clinical study titled "Quarterback 2b - Sequential Therapy With Reduced Dose Chemoradiotherapy for HPV Oropharynx Cancer". The purpose of this study is to establish the efficacy and toxicity of low dose chemoradiotherapy after induction chemotherapy in patients with locally advanced HPV+ oropharynx cancer and establish prognostic factors that would apply to help select patients for this treatment in the future.
What is the current status of trial NCT02945631?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 43 participants. The study started on 2016-04-25. Estimated completion is 2027-12.
What conditions does trial NCT02945631 study?
This clinical trial studies the following conditions: Locally Advanced HPV Positive Oropharynx Cancer.
What interventions are being tested in trial NCT02945631?
The interventions under investigation include: PTV56 (RADIATION), PTV50.4 (RADIATION).
Who is sponsoring clinical trial NCT02945631?
This trial is sponsored by Icahn School of Medicine at Mount Sinai, which has 708 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02945631 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.